Search results for "Metabolic disease"

showing 10 items of 778 documents

Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome

2007

Objective To assess message expression of adiponectin and leptin in visceral and SC fat in women with polycystic ovary syndrome (PCOS) and in control women. Design Prospective clinical trial. Setting Academic medical centers in Mexico City, Mexico and New York, New York. Patient(s) Women with PCOS and control women. Intervention(s) Surgical biopsies of visceral (omental) and subcutaneous (SC) adipose tissue, fasting blood samples, and ultrasound measurements of visceral and SC fat. Main Outcome Measure(s) Messenger RNA assessment of adiponectin and leptin in adipose tissue samples; serum measurements of adiponectin, leptin, glucose, insulin, and hormone levels; measurements of fat quantity …

AdultBlood GlucoseLeptinmedicine.medical_specialtymedicine.medical_treatmentAbdominal FatNew YorkSubcutaneous FatAdipokineAdipose tissueBody Mass IndexSettore MED/13 - EndocrinologiaInsulin resistanceInternal medicineAbdominal fat adiponectin leptin polycystic ovary syndrome insulin resistancemedicineHumansInsulinProspective StudiesRNA MessengerMexicoUltrasonographyAdiponectinbusiness.industryLeptinInsulinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineCase-Control StudiesFemaleAdiponectinInsulin ResistancebusinessBody mass indexhormones hormone substitutes and hormone antagonistsPolycystic Ovary Syndrome
researchProduct

Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exe…

2005

Aim: The aim of this study was to investigate the role of skeletal muscle fibre type in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) during a 2-year exercise anddietary intervention. Methods: Muscle biopsies (musculus vastus lateralis) were taken from 22 subjects belonging to the intervention group of the Finnish Diabetes Prevention Study [1]. According to their myosin heavy chain (MHC) profile at the baseline, the subjects were divided into two groups: IGT s l o w (n = 10) with a high proportion of MHC I isoforms and IGT f a s t (n = 12) with a high proportion of MHC II isoforms in the vastus lateralis muscle. The intervention con…

AdultBlood GlucoseMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiet Reducingendocrine system diseasesVastus lateralis muscleEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalCarbohydrate metabolismImpaired glucose toleranceGlycogen Synthase Kinase 3EndocrinologyInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceWeight LossInternal MedicinemedicineHumansAerobic exerciseObesityMuscle SkeletalGlycogen synthaseExerciseAgedMyosin Heavy Chainsbiologybusiness.industrynutritional and metabolic diseasesSkeletal muscleMiddle Agedmedicine.diseaseCombined Modality Therapymedicine.anatomical_structureEndocrinologybiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsFollow-Up StudiesDiabetes, Obesity and Metabolism
researchProduct

Glycated serum proteins and glucose tolerance

1988

Glycated serum proteins (GSP), stable glycated hemoglobin (HbA1c) together with some metabolic parameters were evaluated in 120 subjects, 30 with normal glucose tolerance (NGT), 30 with impaired glucose tolerance (IGT), 30 with non-insulin-dependent diabetes mellitus (NIDD), and 30 with insulin-dependent diabetes mellitus (IDD). GSP levels were significantly higher in IGT, NIDD and IDD than in NGT. HbA1c levels were not significantly higher in IGT in comparison with NGT, but were significantly higher in NIDD and in IDD than in NGT and IGT. GSP correlated better than HbA1c with all metabolic parameters considered. Taking into account the distribution of the values, GSP showed a smaller overl…

AdultBlood GlucoseMalemedicine.medical_specialtyGlycosylationendocrine system diseasesEndocrinology Diabetes and MetabolismImpaired glucose toleranceHba1c levelchemistry.chemical_compoundEndocrinologystomatognathic systemReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansTriglyceridesGlycated HemoglobinGlucose tolerance testmedicine.diagnostic_testbusiness.industryCholesterolnutritional and metabolic diseasesBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood proteinsCholesterolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2chemistryHyperglycemiaMetabolic control analysisFemaleGlycated hemoglobinbusinesshormones hormone substitutes and hormone antagonistsActa Diabetologica Latina
researchProduct

Sympathovagal balance and 1-h postload plasma glucose in normoglucose tolerant hypertensive patients.

2015

AIMS: Normoglucose tolerant (NGT) subjects with a 1-h postload plasma glucose (PLPG) value ≥155 mg/dL have an increased risk of type-2 diabetes and subclinical organ damage. Heart rate variability (HRV) reflects cardiac autonomic balance, frequently impaired in course of diabetes. At this time, no data support the association between 1-h PLPG and HRV; thus, we investigated the possible association between 1-h PLPG and HRV. METHODS: We enrolled 92 never-treated hypertensive subjects (56 women, 36 men), aged 55 ± 9.8 years. During OGTT, the patients underwent electrocardiographic recordings to evaluate HRV in the time domain (SDNN). Insulin sensitivity was assessed by Matsuda index. RESULTS: …

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesglucose toleranceInsulin resistance Heart rate variability Glucose tolerance Essential hypertensionEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyEssential hypertensionAutonomic Nervous Systeminsulin resistance heart rate variability glucose tolerance essential hypertensionImpaired glucose tolerance03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceHeart RateInternal medicineDiabetes mellitusinsulin resistanceGlucose IntoleranceInternal MedicineMedicineHeart rate variabilityHomeostasisHumansSubclinical infectionBalance (ability)Agedbusiness.industryInsulinheart rate variabilityessential hypertensionnutritional and metabolic diseasesGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyDiabetes Mellitus Type 2HypertensionCardiologyFemalebusinesshormones hormone substitutes and hormone antagonists
researchProduct

Glycaemic variability and inflammation in subjects with metabolic syndrome.

2008

Subjects who develop diabetes have an increased cardiovascular risk even before the appearance of diabetes. The aim of this study was to investigate the glycaemic variability measured by continuous glucose monitoring (CGM CV%) in nondiabetic subjects with metabolic syndrome (MS) and to explore if glycaemic variability was associated with circulating levels of interleukin-6 (IL-6), a proinflammatory cytokine, or with an anti-inflammatory factor like adiponectin. Three groups of obese subjects with (MS+: 6m, 8f; BMI 33.1 ± 1.4 mean ± SEM) or without metabolic syndrome (MS−: 2m, 4f; BMI 29.2 ± 2.2) and with MS associated with type 2 diabetes (MS/T2D: 3m, 5f; BMI 32.9 ± 1.4) were investigated. …

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMonitoring AmbulatoryBlood sugarType 2 diabetesBody Mass IndexEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansObesityMetabolic SyndromeAdiponectinbusiness.industryInsulinReproducibility of Resultsnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseObesityEndocrinologyFemaleWaist CircumferenceMetabolic syndromeVariabilità glicemica flogosi sindrome metabolicabusiness
researchProduct

The effect of growth hormone ( GH ) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real‐life data from th…

2015

SummaryObjective To assess the effect of 4 years’ growth hormone (GH) replacement on glucose homeostasis and evaluate factors affecting glycosylated haemoglobin (HbA1c) in adults with growth hormone deficiency (GHD). Design NordiNet® International Outcome Study, a noninterventional study, monitors long-term effectiveness and safety of GH replacement [Norditropin® (somatropin), Novo Nordisk A/S] in real-life clinical practice. Patients Nondiabetic patients (n = 245) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH replacement and HbA1c values at baseline and 4 years were included in the analysis. Measurements Changes from baseline (∆) to 4 years in HbA1c, fasting plasma glucose…

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencyImpaired glucose toleranceYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusDiabetes MellitusmedicineHomeostasisHumansGlucose homeostasisYoung adultAgedAged 80 and overGlycated Hemoglobinbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseSomatropinTreatment OutcomeEndocrinologyGrowth HormoneFemalebusinessBody mass indexClinical Endocrinology
researchProduct

Prevalence of diabetes mellitus and impaired glucose tolerance in cystic fibrosis.

1990

The aim of this study was to evaluate the prevalence of impaired glucose tolerance or diabetes mellitus in 99 patients (53 M, 46 F; mean age 10.5 +/- 6.9 years), with cystic fibrosis. Glucose tolerance was evaluated in all patients without overt diabetes using the oral glucose tolerance test (OGTT). Six patients showed a pathological OGTT and 2 patients had insulin-requiring diabetes mellitus. The mean age of the patients with impaired glucose tolerance was significantly higher than that of the subjects with normal glucose metabolism (p less than 0.0001). Patients with overt diabetes mellitus were the oldest subjects in the study group.

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesAdolescentCystic FibrosisEndocrinology Diabetes and MetabolismStatistics as TopicCarbohydrate metabolismGastroenterologyCystic fibrosisImpaired glucose toleranceEndocrinologyInternal medicineDiabetes mellitusEpidemiologyInternal MedicinemedicineDiabetes MellitusPrevalenceHumansChildPathologicalGlucose tolerance testmedicine.diagnostic_testbusiness.industrynutritional and metabolic diseasesInfantGeneral MedicineGlucose Tolerance Testmedicine.diseaseEndocrinologyChild PreschoolFemalebusinessComplicationActa diabetologica latina
researchProduct

Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection.

2013

Background: An important task in diabetes management is detection of hypoglycemia. Professional continuous glucose monitoring (CGM), which produces a glucose reading every 5 min, is a powerful tool for retrospective identification of unrecognized hypoglycemia. Unfortunately, CGM devices tend to be inaccurate, especially in the hypoglycemic range, which limits their applicability for hypoglycemia detection. The objective of this study was to develop an automated pattern recognition algorithm to detect hypoglycemic events in retrospective, professional CGM. Method: Continuous glucose monitoring and plasma glucose (PG) readings were obtained from 17 data sets of 10 type 1 diabetes patients und…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringHypoglycemiaSensitivity and SpecificityAutomationDiabetes managementBlood Glucose Self-MonitoringDiabetes mellitusInternal MedicineMedicineHumansIntensive care medicineGlycemicMonitoring PhysiologicRetrospective StudiesType 1 diabetesbusiness.industryContinuous glucose monitoringBlood Glucose Self-Monitoringnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Original ArticlebusinessAlgorithmsJournal of diabetes science and technology
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Classical cardiovascular risk factors according to fasting plasma glucose levels

2007

To compare the prevalence of classical cardiovascular risk factors (CVRF) and metabolic syndrome (MetS) in our population according to fasting plasma glucose levels (FPG).We have studied 344 subjects between 20-70 years of age, recruited in a Primary Care Clinic. Subjects were divided into four groups according to their fasting plasma glucose (FPG) values: normal plasma glucose (NG) when FPG5.6 mmol/L; FPG between 5.6 and 6.0 mmol/L (FPG1); FPG between 6.1-6.9 mmol/L (FPG2); and diabetes (DM) FPGor = 7 mmol/L or previous diagnosis of diabetes. Cardiovascular risk factors (hypertension, TC/HDL-C index and Apo B values), presence of the MetS and indirect measure of insulin resistance (HOMA) w…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesPopulationCardiovascular risk factorsComorbiditySeverity of Illness IndexRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumanseducationPractical implicationsAgedMetabolic Syndromeeducation.field_of_studyPlasma glucosebusiness.industrynutritional and metabolic diseasesType 2 Diabetes MellitusFastingMiddle AgedImpaired fasting glucosemedicine.diseasePrimary care clinicCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesSpainFemaleMetabolic syndromebusinessEuropean Journal of Internal Medicine
researchProduct